South Africa asks Serum Institute to take back 1 million vaccine doses, says report
South Africa has asked the Serum Institute of India to take back the one million COVID-19vaccine doses the company had s...
South Africa has put its rollout of the Oxford-AstraZeneca vaccine on hold after a study showed "disappointing" results against its new Covid variant.
Scientists say the variant accounts for 90% of new Covid cases in South Africa.
The trial, involving some 2,000 people, found that the vaccine offered "minimal protection" against mild and moderate cases.
But experts are hopeful that the vaccine will still be effective at preventing severe cases.
South Africa has recorded almost 1.5 million coronavirus cases and more than 46,000 deaths since the pandemic began - a higher toll than any other country on the continent.
View SourceThis notice has been removed
The content is no longer available
South Africa has put its rollout of the Oxford-AstraZeneca vaccine on hold after a study showed "disappointing" results against its new Covid variant.
Scientists say the variant accounts for 90% of new Covid cases in South Africa.
The trial, involving some 2,000 people, found that the vaccine offered "minimal protection" against mild and moderate cases.
But experts are hopeful that the vaccine will still be effective at preventing severe cases.
South Africa has recorded almost 1.5 million coronavirus cases and more than 46,000 deaths since the pandemic began - a higher toll than any other country on the continent.
No results found
Try a different search term
Something went wrong
No notices yet
No notices match these filters
Couldn't load notices
You're all caught up 🎉
Sign in to continue to Global Noticeboard
Enter your email to receive a reset link
Create a new password for your account
You are marking this Notice are inappropriate, and you belive it infringes on the Global Noticeboard Community Guidelines (link). Is this so?
Create 3 Noticeboards to earn this Silver level Community Champion Badge.
View all badges that you can earnPlease tell us why you are reporting this content.
Discussion (0)
No comments yet